ロード中...
Risk Prediction Model for Heart Failure and Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer
BACKGROUND: Adjuvant trastuzumab improves survival for women with human epidermal growth factor receptor 2‐positive breast cancer, but increases risk for heart failure (HF) and cardiomyopathy (CM). However, clinical trials may underestimate HF/CM risk because they enroll younger subjects with fewer...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Blackwell Publishing Ltd
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3959671/ https://ncbi.nlm.nih.gov/pubmed/24584736 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.113.000472 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|